Ergomed issue of shares

RNS Number : 0825G

Ergomed plc

01 November 2018

 

PRESS RELEASE

FOR IMMEDIATE RELEASE

Ergomed issues 102,491 shares for acquisition and deferred consideration

London, UK - 1 November 2018: Ergomed plc, (LSE: ERGO) ('Ergomed' or the 'Company'), a company focused on providing specialised services to the pharmaceutical industry, today announces the issue of a total of 102,491 new ordinary shares of 1p each in the Company ("Shares"). Of this amount, 49,390 Shares are being allotted to Dr Michael Forstner as deferred consideration in connection with the acquisition of his epidemiology consulting business announced on 25 May 2018. The remaining 53,101 Shares are being allotted to the seller as part consideration for the acquisition of Pharmacovigilance Services Limited, a small UK-based pharmacovigilance provider with particular expertise in audit and quality management.

An application has been made for the admission to trading on AIM of the Shares ("Admission"). Admission is expected to take place at 8.00am on 7 November 2018. The Shares will rank pari passu in all respects with Ergomed's existing shares in issue. Following Admission, the Company's enlarged issued share capital will comprise 44,991,438 Ordinary Shares with one voting right per share. No shares are held in Treasury. The total number of voting rights in the Company is therefore 44,991,438. This figure of 44,991,438 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

 Enquiries:

Ergomed plc	Tel: [phone]
Stephen Stamp (Chief Executive Officer)
Stuart Jackson (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Mary-Jane Elliott Matthew Neal / Olivia Manser	[e-mail]
MC-Services - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services offering encompasses a complete suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, in addition to a full range of high quality contract research and trial management services (CRO). Leveraging its CRO expertise, Ergomed also has a drug development portfolio of co-development partnerships and wholly-owned programmes. For further information, visit: http://ergomedplc.com

 

END

 

 

MSCLLFSSLFLLIIT